SOURCE: Carl Zeiss Meditec, Inc.

May 07, 2007 09:00 ET

Carl Zeiss Meditec, Inc. Ships Its 500th VISUCAM PRO NM System in the United States

Camera Increases Quality and Simplicity of Fundus Imaging

DUBLIN, CA -- (MARKET WIRE) -- May 7, 2007 -- Carl Zeiss Meditec, Inc. today announced installation of its 500th VISUCAM PRO NM non-mydriatic fundus camera at the Indiana University School of Optometry's Indianapolis Eye Care Center. Designed for routine clinical use, the compact VISUCAM PRO NM offers clinicians enhanced fundus visualization and documentation, and is credited for setting the standard in non-mydriatic ophthalmic photography.

"We are extremely happy with our new VISUCAM and find the camera to be very user friendly with superb image quality," said Brad Sutton, O.D., F.A.A.O., associate professor, Indiana University School of Optometry and clinic director for the Indianapolis Eye Care Center. "The camera's ability to obtain high quality images through small pupils enhances fundus visualization, and its ability to digitally separate images into their red, green and blue components is very helpful in imaging certain pathologies.

"Additionally, the camera has proven to be an invaluable education tool for both our interns in training, as well as for our patients," continued Dr. Sutton.

The VISUCAM PRO NM, which was introduced in June 2005, is designed for routine clinical use by integrating all the elements of retinal photography from image capture to documentation. As a result, the camera optimizes practice efficiency. Visual overview and assessment are possible during review of the photos for in-depth study because once the image is captured, brilliant fundus photos immediately appear on the flat-screen monitor and are automatically stored. Additionally, images are correctly illuminated regardless of the pupil size and fundus color, allowing for accurate image comparison and review, as well as quick image transfer via network, USB stick or DVD.

Clinicians report that the VISUCAM PRO NM has helped to enhance fundus visualization and documentation for their practice, and as a result, significantly improve workflow as well as patient comfort due to shortened, improved exams.

About Carl Zeiss Meditec

Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world's leading medical technology companies. This market position is based on over 160 years of experience in optical innovation. The company has two primary areas of activitiy. In the field of ophthalmology, Carl Zeiss Meditec offers integrated solutions for treating the four main eye diseases: vision defects (refraction), cataracts, glaucoma and retinal disorders. Product innovations range from basic systems such as slit lamps and fundus cameras to standard setting diagnostic systems such as the Humphrey® Field Analyzer, the Stratus OCT™ and the IOLMaster®, through to the surgical microscopes and innovative treatment systems in refractive laser surgery.

In the field of neuro and ENT surgery, Carl Zeiss Meditec is the world's leading provider of surgical microscopes and microsurgical visualisation solutions for a very broad range of applications, such as tumour and vascular surgery in the head region and/or spinal surgery. The most recent example of our innovative performance in the area of microsurgery is the OPMI Pentero® visualization system, which allows efficient and ergonomic patient treatment.

Carl Zeiss Meditec's medical technology portfolio is rounded off by visualization systems for doctors in private practice and promising future technologies such as intraoperative radiation therapy, which allows the targeted treatment of breast cancer and brain cancer directly during surgery.

Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in Germany (Carl Zeiss Meditec Surgical GmbH and Carl Zeiss Meditec Vertriebsgesellschaf mbH), the USA (Carl Zeiss Meditec, Inc., Dublin, California), in Japan (Carl Zeiss Meditec Co., Ltd., Tokyo), Spain (Carl Zeiss Meditec Iberia S.A., Madrid) and France (Ioltech SAS, La Rochelle, and Carl Zeiss Meditec France SAS, Le Pecq).

Thirty-five percent of the Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss, one of the world's leading international groups engaged in the optical and opto-electronics industry. For additional information, visit

Contact Information